These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1134 related items for PubMed ID: 22461615

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH.
    J Biol Chem; 2007 Aug 31; 282(35):25604-12. PubMed ID: 17599906
    [Abstract] [Full Text] [Related]

  • 23. Amino Acids Attenuate Insulin Action on Gluconeogenesis and Promote Fatty Acid Biosynthesis via mTORC1 Signaling Pathway in trout Hepatocytes.
    Dai W, Panserat S, Plagnes-Juan E, Seiliez I, Skiba-Cassy S.
    Cell Physiol Biochem; 2015 Aug 31; 36(3):1084-100. PubMed ID: 26112996
    [Abstract] [Full Text] [Related]

  • 24. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J.
    PLoS One; 2015 Aug 31; 10(7):e0132880. PubMed ID: 26176608
    [Abstract] [Full Text] [Related]

  • 25. Dissecting mammalian target of rapamycin to promote longevity.
    Mendelsohn AR, Larrick JW.
    Rejuvenation Res; 2012 Jun 31; 15(3):334-7. PubMed ID: 22758368
    [Abstract] [Full Text] [Related]

  • 26. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.
    Veilleux A, Houde VP, Bellmann K, Marette A.
    Mol Endocrinol; 2010 Apr 31; 24(4):766-78. PubMed ID: 20203102
    [Abstract] [Full Text] [Related]

  • 27. Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium.
    Leontieva OV, Demidenko ZN, Blagosklonny MV.
    Cell Death Dis; 2014 May 08; 5(5):e1214. PubMed ID: 24810050
    [Abstract] [Full Text] [Related]

  • 28. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.
    Smrz D, Kim MS, Zhang S, Mock BA, Smrzová S, DuBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD, Gilfillan AM.
    Blood; 2011 Dec 22; 118(26):6803-13. PubMed ID: 22053105
    [Abstract] [Full Text] [Related]

  • 29. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X, Wang X, Xu T, Zhong S, Shen Z.
    Tumour Biol; 2015 Jul 22; 36(7):5273-81. PubMed ID: 25666752
    [Abstract] [Full Text] [Related]

  • 30. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M, Gillick JL, Neil J, Tobias M, Thwing ZE, Murali R.
    Adv Biol Regul; 2015 Jan 22; 57():64-74. PubMed ID: 25442674
    [Abstract] [Full Text] [Related]

  • 31. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis.
    Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM.
    PLoS Genet; 2015 Jul 22; 11(7):e1005291. PubMed ID: 26132202
    [Abstract] [Full Text] [Related]

  • 32. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism.
    Kumar A, Lawrence JC, Jung DY, Ko HJ, Keller SR, Kim JK, Magnuson MA, Harris TE.
    Diabetes; 2010 Jun 22; 59(6):1397-406. PubMed ID: 20332342
    [Abstract] [Full Text] [Related]

  • 33. Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice.
    Tripathy S, Jump DB.
    J Lipid Res; 2013 Jan 22; 54(1):71-84. PubMed ID: 23099444
    [Abstract] [Full Text] [Related]

  • 34. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
    Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA.
    Mol Cancer Ther; 2011 Aug 22; 10(8):1394-406. PubMed ID: 21673091
    [Abstract] [Full Text] [Related]

  • 35. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
    Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM.
    PLoS Biol; 2009 Feb 10; 7(2):e38. PubMed ID: 19209957
    [Abstract] [Full Text] [Related]

  • 36. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z, Chen J, Yang J, Bai X.
    Curr Cancer Drug Targets; 2016 Feb 10; 16(4):288-304. PubMed ID: 26563881
    [Abstract] [Full Text] [Related]

  • 37. Hepatic FOXO1 Target Genes Are Co-regulated by Thyroid Hormone via RICTOR Protein Deacetylation and MTORC2-AKT Protein Inhibition.
    Singh BK, Sinha RA, Zhou J, Tripathi M, Ohba K, Wang ME, Astapova I, Ghosh S, Hollenberg AN, Gauthier K, Yen PM.
    J Biol Chem; 2016 Jan 01; 291(1):198-214. PubMed ID: 26453307
    [Abstract] [Full Text] [Related]

  • 38. Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.
    Facompre ND, Sinha I, El-Bayoumy K, Pinto JT, Sinha R.
    Int J Cancer; 2012 Nov 01; 131(9):2134-42. PubMed ID: 22307455
    [Abstract] [Full Text] [Related]

  • 39. Rapamycin regulates the phosphorylation of rictor.
    Akcakanat A, Singh G, Hung MC, Meric-Bernstam F.
    Biochem Biophys Res Commun; 2007 Oct 19; 362(2):330-3. PubMed ID: 17707343
    [Abstract] [Full Text] [Related]

  • 40. Acute rapamycin treatment improved glucose tolerance through inhibition of hepatic gluconeogenesis in rainbow trout (Oncorhynchus mykiss).
    Dai W, Panserat S, Terrier F, Seiliez I, Skiba-Cassy S.
    Am J Physiol Regul Integr Comp Physiol; 2014 Nov 15; 307(10):R1231-8. PubMed ID: 25163922
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.